Introduction of lamivudine for the treatment of chronic hepatitis B: Expected clinical and economic outcomes based on 4-year clinical trial data

Journal of Gastroenterology and Hepatology (Australia)

Volumn 17, Issue 2, 2002, Pages 153-164

  Crowley, Steven ^b   Tognarini, David ^a   Desmond, Paul ^c   Lees, Michael ^d   Saal, Gauri ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d M TAG Pty Ltd   (Australia)

Author keywords

Chronic hepatitis B; Cost effectiveness; Decision analysis; Lamivudine; interferon

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; LAMIVUDINE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG EFFECT; FEMALE; FOLLOW UP; HEALTH CARE COST; HEPATITIS B; HUMAN; LIFE EXPECTANCY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; QUESTIONNAIRE; SENSITIVITY ANALYSIS; SEROCONVERSION; TREATMENT OUTCOME;

EID: 0036230712     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2002.02673.x     Document Type: Article

References (49)

1. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia
2. Natural history of chronic hepatitis B virus infection
3. The incidence of hepatitis B infection in Australia; an epidemiological review
4. Hepatitis B: Diagnosis, prevention, and treatment
5. Effect of alpha interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B - A meta-analysis
6. Therapy of viral hepatitis
7. A one-year trial of lamivudine for chronic hepatitis B
8. Lamivudine as initial treatment for chronic hepatitis B in the United States
9. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B
10. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial
11. Enhanced HBeAg seroconversion rates in Chinese patients on lamivudine
12. Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV patients
13. Lamivudine treatment reduces progression to cirrhosis in patients with chronic hepatitis B
14. Clinical safety profile of lamivudine treatment in a large cohort of hepatitis B patients
15. Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B
16. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B
17. Lamivudine treatment for decompensated cirrhosis due to hepatitis B. A multicenter longitudinal study
18. Long term follow up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B
19. Long-term remission of chronic hepatitis B after alpha-interferon therapy
20. Predictors of HBeAg seroconversion in chronic hepatitis B patients treated with lamivudine
21. The potential impact of lamivudine (100mg) on the clinical management of chronic hepatitis B in Australia
22. The Assessment of Quality of Life (AQOL) Instrument: A psychometric measurement of health related quality of life
23. The treatment effect of alpha interferon in chronic hepatitis B is independent of pretreatment variables. Results based on individual patient data from 10 clinical controlled trials
24. The long term effect of treatment with interferon alpha 2A in chronic hepatitis B
25. Long-term effect of interferon therapy in chronic hepatitis B
26. Durable HBeAg and HBsAg seroconversions after lamivudine for chronic hepatitis B
27. The development of cirrhosis in patients with chronic type B hepatitis; a prospective study
28. Natural history and prognostic factors for chronic hepatitis type B
29. Cost-effectiveness of interferon-alpha 2B treatment for hepatitis B e antigen-positive chronic hepatitis B
30. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver
31. The natural course of hepatitis B surface antigen-positive chronic active hepatitis in Taiwan
32. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: A prospective study
33. Hepatitis B related sequelae: Prospective study in 1400 hepatitis B surface antigen-positive Alaskan native carriers
34. Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B
35. Hepatocellular carcinoma and hepatitis B virus
36. Effect of interferon-alpha on progression to cirrhosis to hepatocellular carcinoma: A retrospective cohort study
37. Hepatocellular carcinoma in patients with cirrhosis
38. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: A multicenter study
39. A placebo controlled study of lamivudine and interferon α-2b in patients with chronic hepatitis B who previously failed interferon therapy
40. Lamivudine for suppression of viral replication in patients with decompensated chronic hepatitis B
41. Multicenter study of lamivudine for hepatitis B after liver transplantation
42. Lamivudine for prevention of recurrent hepatitis B after liver transplantation: Final results of a U.S./Canadian Multicenter trial